-
Flubendazole Autophagy Research Workflows
2026-09-12
Flubendazole offers a DMSO-compatible way to introduce autophagy perturbation into cancer-cell, extracellular-vesicle, and migration assays. This practical workflow connects compound handling with the macrophage-EV–miR-660 breast cancer model while separating autophagy-associated effects from general growth arrest or toxicity.
-
Torin2: Designing Mechanistic Cell-Death Assays
2026-09-12
Discover how Torin2, a potent mTOR inhibitor, can be used to separate pathway suppression from the mechanism of cell death. This guide integrates mTOR pharmacology with recent evidence that Pol II degradation can activate death independently of transcriptional loss.
-
Arrb2–6-ketoLCA Signaling in Hepatic IRI
2026-09-11
The reference study identifies hepatocyte β-arrestin 2 (Arrb2) as a regulator of hepatic ischemia–reperfusion injury, linking hepatocyte metabolic output to M2 macrophage polarization through 6-ketoLCA. By combining clinical samples, hepatocyte-focused mouse genetics, ischemia–reperfusion and hypoxia–reoxygenation models, and metabolomics, the work provides a mechanistic framework for studying sterile inflammation in liver transplantation.
-
Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells
2026-09-11
The reference study identifies a small-molecule strategy for reducing SPP1 expression in tumor-associated macrophages and packages lead compounds into a TAM-avid nanoconstruct. Its combination of phenotypic screening, myeloid-cell targeting, and validation across murine tumor models provides a practical framework for developing therapies that reprogram tumor-supportive immunity rather than simply depleting macrophages.
-
Digoxin: From Ion Pumps to Translational Strategy
2026-09-10
Digoxin is more than a cardiac glycoside: it is a mechanistically defined Na+/K+ ATPase pump inhibitor that connects ion transport, cardiac contractility modulation, and cell-context-dependent antiviral research. This thought-leadership article examines how to translate Digoxin from arrhythmia treatment research and congestive heart failure animal models into disciplined CHIKV assay design, while defining the boundaries that prevent overinterpretation.
-
BCS Biowaivers for Taltirelin ODTs and IR Formulations
2026-09-10
The reference study experimentally examined whether dissolution testing could support BCS-based biowaivers for orally disintegrating tablets compared with immediate-release formulations. Its findings identify Taltirelin as a BCS class III example with very rapid dissolution and show why dose-to-solubility ratio remains important when interpreting formulation equivalence.
-
Ridaforolimus: From mTOR Signal to Assay Decision
2026-09-09
Ridaforolimus (Deforolimus) is a potent mTOR-pathway probe for connecting signaling changes with proliferation, apoptosis, angiogenesis, and senescence-related phenotypes. This guide presents a phenotype-first assay strategy grounded in machine-learning-enabled senolytic discovery.
-
Uridine, Trisodium Salt for RNA Workflows
2026-09-09
Uridine, Trisodium Salt supports controlled RNA metabolism, cellular biosynthesis, and vascular response experiments when researchers distinguish nucleoside feeding from direct in vitro transcription. This guide connects high-purity reagent handling with RNA-mediated genome-engineering workflows inspired by PRINT, while emphasizing assay controls and troubleshooting.
-
Topotecan and Replication Stress: A Translational Playbook
2026-09-08
Topotecan is more than a cytotoxic agent: it is a mechanistic probe for replication-fork vulnerability, DNA repair dependence, and translational model selection. This thought-leadership guide connects Topotecan or SKF104864 exposure to Dna2 biology, glioma assays, pediatric tumor models, and clinically relevant combination strategies.
-
Romidepsin (FK228) Research Workflows
2026-09-07
Build reproducible HDAC1/2 inhibition workflows with Romidepsin (FK228), from solvent handling and 72-hour viability assays to apoptosis, chromatin, and proteomics readouts. The approach also shows how a recent RFC4–Notch study can inform orthogonal assay selection without overstating mechanistic overlap.
-
Coronavirus Macrodomain Restrains PARP Antiviral Activity
2026-09-07
Grunewald and colleagues showed that coronavirus macrodomains counter host PARP-dependent ADP-ribosylation, thereby preserving viral replication while limiting interferon induction. Using mutant and wild-type viruses, pharmacological inhibition, and PARP12 or PARP14 knockdown, the study identifies a mechanistic link between viral macrodomain activity and innate immune regulation.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-05
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer cell proliferation, and metabolism. This dossier-based guide covers preparation, assay setup, QC, and interpretation, but the compound should not be used as a substitute for clinical efficacy evidence or model-specific optimization.
-
MEHP, AhR, and Ovarian Follicle Toxicity
2026-09-05
This study identifies aryl hydrocarbon receptor activation as a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. By combining MEHP exposure with pharmacological AhR inhibition, the authors connect impaired follicle growth, reduced estrogen production, and altered estrogen-responsive gene expression within a single experimental framework.
-
Naloxone Hydrochloride Research Workflows
2026-09-04
Build more informative opioid assays with Naloxone hydrochloride, from receptor-blockade and withdrawal models to neural stem cell proliferation modulation. This guide combines product handling, reference-informed behavioral design, cross-domain applications, and troubleshooting for more reproducible research.
-
Bsa I (RNase-free): Practical DNA Workflow
2026-09-04
Bsa I (RNase-free) supports sequence-directed DNA cleavage for gene cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination should be minimized. This guide covers product-specific parameters and practical setup controls; the enzyme is for scientific research only and not for diagnostic, clinical, or medical use.